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ABSTRACT The International Standards for Tuberculosis Care define the essential level of care for
managing patients who have or are presumed to have tuberculosis, or are at increased risk of developing
the disease. The resources and capacity in the European Union (EU) and the European Economic Area
permit higher standards of care to secure quality and timely TB diagnosis, prevention and treatment. On
this basis, the European Union Standards for Tuberculosis Care (ESTC) were published in 2012 as
standards specifically tailored to the EU setting. Since the publication of the ESTC, new scientific evidence
has become available and, therefore, the standards were reviewed and updated.
A panel of international experts, led by a writing group from the European Respiratory Society (ERS)
and the European Centre for Disease Prevention and Control (ECDC), updated the ESTC on the basis of
new published evidence. The underlying principles of these patient-centred standards remain unchanged.
The second edition of the ESTC includes 21 standards in the areas of diagnosis, treatment, HIV and
comorbidities, and public health and prevention.
The ESTC target clinicians and public health workers, provide an easy-to-use resource and act as a
guide through all the required activities to ensure optimal diagnosis, treatment and prevention of TB.
This document was endorsed by the by the ERS Science Council and Executive Committee in April 2018, and approved
by ECDC in March 2018.
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Introduction
With 58 994 tuberculosis (TB) cases notified in the European Union and European Economic Area (EU/
EEA; refers to Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland,
France, Germany, Greece, Hungary, Iceland, Republic of Ireland, Italy, Latvia, Liechtenstein, Lithuania,
Luxembourg, Malta, The Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain,
Sweden and the UK) member states in 2016 [1], TB continues to be a priority public health challenge in
this setting. Although several EU/EEA countries are progressing towards sustained low levels of TB
incidence and some towards the pre-elimination phase (defined as less than 10 cases per million
population [1–3]), great diversity in TB disease burden remains within the sub-region [1]. Drug-resistant
TB, multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose a specific public
health threat in many countries [4]. Furthermore, documenting the prevalence of HIV co-infection among
TB cases is still compromised by sub-optimal reporting in several countries [5, 6].
While EU/EEA countries adopted the key principles of TB control and elimination through the
Europe-specific, consensus-based documents born within the Wolfheze initiative [7] and subsequent
documents [2], a uniform set of guidelines summarising essential standards to guide European clinicians
and healthcare workers was developed only in 2012 [8]. These European Union Standards for Tuberculosis
Care (ESTC) were based on the second version of the International Standards for Tuberculosis Care (ISTC)
issued in 2009 [9]. The documents were developed by experts selected to include the perspectives of several
countries, organisations, national TB programmes, and scientific and civil societies, as well as representatives
of the affected communities, which endorsed them for universal (ISTC) or EU/EAA countries’ use (ESTC).
Both ISTC and ESTC [8–11] prescribe a widely accepted level of TB care, to guide all healthcare providers
and clinicians, both public and private, in achieving optimal standards in managing individuals who have
active TB, latent TB infection (LTBI) or signs and symptoms compatible with the disease. The standards
are designed to complement existing national or international guidelines and are consistent with World
Health Organization (WHO) definitions and recommendations [12].
The original ESTC include 21 standards organised into four sections: 1) standards for diagnosis,
2) standards for treatment, 3) standards for addressing HIV co-infection and other comorbidities and
4) standards for public health [8]. The standards are a living document, and will thus be revised as
technology and circumstances change. In 2014, the third edition of the ISTC was published [10]. An
assessment and a survey among European Respiratory Society (ERS) members and European Centre for
Disease Prevention and Control (ECDC) contacts concluded that a revision of the ESTC would be
appropriate [13, 14].
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The specific mix of characteristics among the EU/EEA member states which justified the development of
standards specifically tailored to the EU context are still valid, and are summarised below [8, 11, 15]:
1) Although the majority of EU/EEA countries have a low incidence of TB, a number of member states
have intermediate TB levels, with varying incidence of MDR-TB and TB-HIV co-infection. Furthermore,
several countries located at the eastern border of the EU are neighbours to non-EU countries with a high
TB and MDR-TB burden.
2) TB services are fully integrated and merged within the health system in the majority of EU/EEA
countries. This leads to individual country peculiarities in allocating responsibilities for the optimal
delivery of TB care.
3) The EU/EEA countries have a long-established tradition of TB control that has evolved over past
decades. New tools and high standards of diagnosis and care are often implemented in EU/EEA countries.
4) The EU/EEA is committed to pursuing the elimination of TB, sharing a common platform based on
the Wolfheze documents and subsequent documents; the Global End TB Strategy and its related action
plan specific to the European region; as well as the surveillance system driven by ECDC and WHO
Regional Office for Europe [2, 16–22].
The purpose of this document is to incorporate the new scientific evidence that has become available after
the publication of the ESTC in 2012.
Methods
A collaborative process, jointly led by the ERS and the ECDC, was initiated in 2016 to revise the ESTC.
The process received input from an ERS task force. The task force included a panel of experts representing
the ERS, other international societies and organisations (World Health Organization, the UNION, KNCV
Tuberculosis Foundation), national TB programmes, civil society, and affected communities. All task force
members provided a conflict of interest declaration, in line with ERS regulations.
This update builds upon the main areas outlined in the previous ESTC edition, i.e. diagnosis, treatment,
HIV and comorbidities, and public health and prevention. The ERS has taken the lead in developing the
clinically related standards and ECDC has done the same for the public health standards. After conducting
an initial scoping search, it was determined that sufficient relevant evidence was already available for an
update of ESTC. Hence, no systematic reviews were conducted as part of the ESTC updating process.
New evidence was identified through a targeted, non-systematic literature search. The search focused on
evidence-based guidelines, systematic reviews/meta-analyses, peer-reviewed scientific articles, institutional
reports and policy recommendations produced after the publication of the first edition of the ESTC (i.e.
2012). Relevant evidence was retrieved after consulting the expert panel, institutional websites and selected
electronic databases, i.e. Medline (www.ncbi.nlm.nih.gov/pubmed/), PROSPERO (www.crd.york.ac.uk/
PROSPERO/) and the Cochrane Database of Systematic Reviews (www.cochranelibrary.com/).
Task force members assessed the synopsis of the evidence and provided their written input for the revision
of the 21 standards and their supporting enablers for implementation. A writing committee consisting of
six experts (four from ERS and two from ECDC) led the writing process of the document (identified as
“equal contributors” in the author list). After three discussion rounds, consensus was reached and the final
document was approved. All co-authors participated in the entire process and contributed to the final
document.
This document provides up-to-date standards for tuberculosis care tailored to the EU and the EEA on
the basis of recently published policy statements and international guidelines, in particular those listed in
table 1.
The final ESTC manuscript was developed according to the ERS rules for official statements before being
peer reviewed by the European Respiratory Journal. In parallel the document gained clearance by ECDC.
How to read the document
Divided into four sections (diagnosis, treatment, HIV and comorbidities, and public health), 21 standards
are defined, following the structure of the first version of the ESTC. For each standard, it is indicated if, in
comparison with the previous version of the ESTC, a given standard remained unchanged or underwent
modifications. Table 2 summarises all the changes. Under the heading “EU-specific requirements” further
considerations are provided. When necessary, notes are listed after each standard, to further define and
explain specific components that the expert group deemed important to clarify.
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Standards for tuberculosis diagnosis
Standard 1 (unchanged)
All persons presenting with signs, symptoms, history or risk factors compatible with tuberculosis should
be evaluated for pulmonary and/or extrapulmonary tuberculosis.
Notes
The most common symptom of pulmonary TB is persistent cough with or without sputum production for
more than 2–3 weeks [10], while haemoptysis (coughing up blood) is more unusual. These signs and
symptoms are common in a wide range of respiratory conditions including acute respiratory infections
(ARI) and acute exacerbation of chronic obstructive pulmonary disease (COPD). Respiratory symptoms
can be accompanied by fever, night sweats and weight loss. For extrapulmonary TB, organ-specific signs
and symptoms may occur. Individuals may also have TB, without specific signs and symptoms of disease,
especially those who are immunosuppressed [33].
It is important to question the patient with regard to TB. For example, a history of TB in the family,
history of previous contact with TB as well as previous TB diagnosis and/or treatment, and any condition
attenuating the host immune system [10] are common risk factors for TB that should be considered as
relevant to the diagnosis. TB in a child is always a “sentinel event” for recent transmission (e.g. a source
case is likely to exist in the family or in their class [34]).
In the EU setting, TB is not the leading cause of persistent cough. Also, cough is not necessarily the most
common symptom of TB disease [35].
Standard 2 (changed)
All patients (adults, adolescents and children who are capable of producing sputum) thought to have
pulmonary tuberculosis should have at least two sputum specimens submitted for microscopic
examination and one for rapid testing for the identification of tuberculosis and drug resistance using an
internationally recommended (rapid) molecular test. The sample should be sent for liquid culture and, if
TABLE 1 Core documents consulted for this update
Document Type of
publication
Year Were systematic
reviews
conducted?
Was the GRADE
approach
applied?
Other relevant information
1 WHO definitions and reporting
framework for TB [23]
Policy
document
2013 No No Developed through a consultation process
2 ISTC (third edition) [10] Standards of
care
2014 No No Builds upon existing WHO guidelines and policy
statements
3 WHO TB elimination framework
for low-incidence countries [20]
Policy
document
2014 No No Developed through revision of existing WHO
policy documents and guidelines, and expert
opinion consultation
4 WHO policy framework for
implementation of TB
diagnostics [24]
Policy
document
2015 No Yes
5 ATS/CDC/IDSA guidelines for TB
diagnosis [25]
Clinical
guideline
2017 No Yes A comprehensive but non-systematic literature
review was conducted to synthesise the
evidence
6 ATS/IDSA/CDC guidelines for
treatment of drug-susceptible
TB [26, 27]
Clinical
guideline
2016 Yes Yes
7 WHO treatment guidelines for
drug-resistant TB [28, 29]
Clinical
guideline
2016 Yes Yes
8 WHO treatment guidelines for
drug-susceptible TB [30]
Clinical
guideline
2017 Yes Yes
9 WHO guidelines on the
management of latent TB
infection [31, 32]
Clinical
guideline
2015 Yes Yes
10 WHO compendium of guidelines
and associated standards [12]
Policy
document
2017 No Yes The document consolidates WHO policy
recommendations and outlines WHO’s
standards for patient-centred care
GRADE: Grading of Recommendations Assessment, Development and Evaluation; WHO: World Health Organization; TB: tuberculosis; ISTC:
International Standards for Tuberculosis Care; ATS: American Thoracic Society; CDC: Centers for Disease Control and Prevention; IDSA:
Infectious Diseases Society of America.
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positive, for culture-based drug susceptibility testing (DST) in a quality-assured laboratory. When possible,
at least one early morning specimen should be obtained. Chest radiography can also be used.
Notes
The order of execution of the microbiological tests mentioned in this and in the following standards will
depend on the laboratory workflow.
The term “internationally recommended (rapid) molecular tests” refers to diagnostic tests validated by
internationally recognised organisations, including WHO. From this point onwards these tests will be
referred to as “rapid molecular tests”.
Based on the EU/EEA practice and definitions [36, 37], quality-assured DST should be performed on
all diagnosed TB patients to rule out drug resistance [16, 37–40]. This should follow international
standards and guidelines with regard to methods used and drug concentrations, for testing of first- and
second-line drugs [16, 18]. Samples sent for bacteriological examinations (sputum smear, culture, DST,
new molecular methods) should be addressed to a mycobacteriology laboratory which implements
TABLE 2 Summary of changes in the second edition compared to the first edition of the European Union Standards for
Tuberculosis Care (ESTC)
Standard Comparison with ESTC
(first edition)
Description of the update
Tuberculosis diagnosis
1 Unchanged
2 Changed Internationally recommended rapid (molecular) tests# added to the laboratory
methods.
3 Changed Internationally recommended rapid (molecular) tests# added to the laboratory
methods.
4 Changed Internationally recommended rapid (molecular) tests# added to the laboratory
methods.
5 Unchanged
6 Changed Internationally recommended rapid (molecular) tests# added to the laboratory
methods.
Tuberculosis treatment
7 Changed The importance of drug susceptibility testing for the selection of the treatment
regimen is highlighted. In addition, patient-centred approaches are mentioned
in the standard.
8 Changed Highlighted that the assessment of drug resistance should be done using
appropriate tests.
9 Changed Simplified.
10 Changed The need for conducting drug susceptibility testing is highlighted and monitoring
of the response to treatment in patients with extrapulmonary tuberculosis and
children is addressed.
11 Changed The standard is harmonised with standards 2–4, 8 and 9.
12 Changed The latest WHO recommendations on treatment regimens are referenced.
13 Changed The option of electronic records and the need for recording of treatment
monitoring are included.
Addressing HIV co-infection
and comorbidities
14 Changed The importance of HIV testing for risk populations is highlighted.
15 Changed The recommendation that all HIV-positive tuberculosis patients should be provided
with antiretroviral therapy has been included.
16 Changed Simplified to allow for alternative preventive treatment regimens.
17 Changed Reworded.
Public health and
tuberculosis prevention
18 Changed Close contacts are specified.
19 Changed The list of groups eligible for testing for latent tuberculosis infection has been
extended. Reference is made to the WHO-recommended regimens for
preventive treatment.
20 Changed Reworded.
21 Unchanged
WHO: World Health Organization. #: the term “internationally recommended rapid (molecular) tests” includes WHO-recommended tests.
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optimal laboratory practices and quality assured procedures according to European and international
recommendations [16, 18, 25].
Quality bacteriological diagnosis includes the WHO-recommended rapid (molecular) assays [12, 41–46]; it
should be done as early as possible (ideally initiated on the day the presumed patient is identified) within
evidence-based diagnostic algorithms and guidelines. Currently available genotypic methods are the
automated real-time nucleic acid amplification technology for rapid and simultaneous detection of
Mycobacterium tuberculosis and rifampicin resistance (e.g. the GeneXpert platform) and the line probe
assays for rapid M. tuberculosis detection and rifampicin resistance or rifampicin- and/or
isoniazid-resistance testing [12, 46–48]. These approaches allow immediate identification of M. tuberculosis
and rifampicin resistance and/or MDR-TB (rifampicin resistance can be considered a proxy of MDR-TB)
[12, 41–46, 49, 50]. Whole genome sequencing (WGS) and WGS-based tools are available for diagnosis
and identification of TB and of drug resistant variants; they are used in some EU countries [51–53].
Molecular diagnostic results must be confirmed by phenotypic testing, i.e. culture-based DST [38, 49, 50];
in case of discrepant results sequencing could be performed from the isolate to identify the mutation and, in
case of high confidence mutations, the isolate should be regarded as resistant. The culture-based DST
confirmation should be done by quality-assured laboratories [54, 55].
At present the choice of molecular methods for the rapid identification of rifampicin and isoniazid
resistance should be that of WHO-recommended rapid diagnostic assays [12, 29]. We expect that in the
near future the role of sequencing as a reference for molecular tests will be recognised and additional
molecular tests will become available in Europe.
Timely, clear and direct communication between the laboratory experts and clinicians is essential to obtain
the optimal link between diagnosis and treatment regimen. The clinician needs to be informed whether
the laboratory performs DST for second-line drugs, and on which drugs [16].
Given that the collection of a third sputum sample has been shown to increase the diagnostic yield by
2–3%, EU/EEA-countries may decide to maintain the previous recommendation of collecting three
sputum samples on the same day (not necessarily on consecutive days) [10, 56].
It is essential to obtain good quality sputum samples in order to ensure reliable bacteriological testing of
the sample [10, 56]. This includes providing clear instructions to the patient, and ensuring appropriate
collection, storage, transportation and processing of sputum samples [57].
To ensure rapid diagnosis a sputum sample should be collected as soon as possible. In addition, it is
recommended to obtain at least one early morning sample from the patient.
Every effort should be made to obtain samples for culture and DST, using the different procedures
available according to evidence-based guidelines (sputum induction, bronchoscopy/bronchoalveolar lavage
and gastric lavage in children [58, 59]).
All MDR-TB strains should be collected and stored at the national level for monitoring drug-resistance
trends and map national and cross-border clusters.
Standard 3 (changed)
For all patients (adults, adolescents and children) presumed to have extrapulmonary tuberculosis,
appropriate specimens from the suspected sites of involvement should be obtained for microbiological
testing (microscopy, rapid molecular tests, culture, species identification, DST with rapid molecular tests
and culture-based techniques) and histopathological examination in quality-assured laboratories.
Notes
This third standard has been accordingly updated to be in line with standard 1 and 2 with regard to
essential, standard diagnosis. So, rapid molecular testing is recommended for all cases [12].
It is essential to use all efforts to obtain bacteriological confirmation from extrapulmonary sites in order to
confirm diagnosis, allow DST and consequently provide optimal and effective treatment; this may include
a more sensitive molecular test [10].
Standard 4 (changed)
All persons with chest radiographic findings suggestive of pulmonary tuberculosis should have sputum
specimens submitted for microscopic examination, rapid molecular tests, culture, species identification and
DST with rapid molecular tests and culture-based techniques in a quality-assured laboratory.
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Note
This standard has been updated to be consistent with the standards 1 and 2 with regard to essential,
standard diagnosis, including rapid molecular testing [10, 12].
Standard 5 (unchanged)
The diagnosis of culture-negative pulmonary tuberculosis should be based on the following criteria: all
bacteriological tests are negative (including direct sputum smear examinations, cultures and rapid
molecular testing); chest radiographic findings compatible with tuberculosis; and lack of response to a trial
of broad spectrum antimicrobial agents (note: because the fluoroquinolones are active against
M. tuberculosis complex, and may cause transient improvement in persons with tuberculosis, their use
should be avoided). In persons who are seriously ill or have known or presumed HIV infection or have
any immune-compromising conditions, the diagnostic evaluation should be expedited and, if clinical
evidence strongly suggests tuberculosis, a course of anti-tuberculosis treatment should be initiated.
EU-specific requirements
In order to ensure quality diagnosis of both pulmonary and extrapulmonary tuberculosis, adequate
samples for bacteriologic examination should be obtained. Sputum induction, bronchoscopy and
bronchoalveolar lavage, gastric washing, biopsy or fine needle aspiration should be used where appropriate
[60]. Samples should be processed using available diagnostic tools [10], and complemented by imaging
(radiology, ultrasound, computed tomography, magnetic resonance imaging, positron emission
tomography-computed tomography) and other necessary examinations performed according to
evidence-based guidelines [10, 25, 61].
WHO-recommended rapid molecular testing [12], culture and DST should be performed on each sample
from patients with presumed pulmonary and extrapulmonary TB, including samples obtained during
surgery or other invasive procedures which usually undergo histological examinations. Surgeons should
thus be advised to save a biological specimen in normal saline for microbiological and molecular biological
examinations and in formalin for histopathological examinations.
Note
Other existing new diagnostic tools, e.g. additional molecular tests and other new techniques in the
development pipeline, should be used within evidence-based diagnostic algorithms and guidelines. Before
introducing any new tool or approach, the evidence has to be validated and have shown efficacy and
patient value.
Standard 6 (changed)
In all children presumed to have intrathoracic (i.e., pulmonary, pleural, and mediastinal or hilar lymph
node) tuberculosis, bacteriological confirmation should be sought through examination of appropriate
biological samples (by expectorated or induced sputum, bronchial secretions, pleural fluid, gastric washings
or endoscopic ultrasound-guided biopsy) by smear microscopy, rapid molecular tests, species identification
and DST with culture-based techniques in a quality-assured laboratory [12, 16–18, 25, 62]. In the event of
negative bacteriological results, a diagnosis of tuberculosis should be based on the presence of
abnormalities consistent with tuberculosis on chest radiography or other imaging, a history of exposure to
an infectious case, evidence of tuberculosis infection (positive tuberculin skin test (TST) and/or a positive
interferon-gamma release assay (IGRA)) [12, 63–66], and/or clinical findings suggestive of tuberculosis
[25]. For children presumed to have extrapulmonary tuberculosis, appropriate specimens from the
suspected sites of involvement should be obtained for microscopy, recommended rapid molecular
tests, species identification and DST with culture-based techniques; and histopathological examination
[12, 59, 67].
Standards for tuberculosis treatment
Standard 7 (changed)
Any practitioner treating a patient for tuberculosis is assuming an important public health responsibility to
prevent ongoing transmission of the infection and the development of drug resistance. To fulfil this
responsibility, the practitioner, in collaboration with public health authorities, must: 1) prescribe an
appropriate regimen (guided by the genotypic and/or phenotypic DST results); 2) perform contact
investigations; 3) assess and promote the patient’s adherence to treatment using a patient-centred
approach in collaboration with family members, local public and/or community health services, and civil
society organisations; and 4) monitor treatment outcomes [10, 68, 69].
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Standard 8 (changed)
All patients (including those with HIV co-infection) who have not been previously treated and are without
drug resistance (assessed by appropriate tests) should receive an internationally accepted first-line
treatment regimen using drugs of known bioavailability. The initial phase should consist of 2 months of
isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E). The continuation phase should
consist of isoniazid and rifampicin given for 4 months (2HRZE/4HR). The doses of anti-tuberculosis
drugs used should conform to international recommendations. Fixed dose combinations of two (isoniazid
and rifampicin), three (isoniazid, rifampicin, and pyrazinamide) and four (isoniazid, rifampicin,
pyrazinamide, and ethambutol) drugs may provide a more convenient form of drug administration.
Notes
The clinician should ensure the correct drug regimen (including four drugs for the intensive phase of
treatment) at the correct dose for a sufficient duration. Daily dosage is strongly recommended [10, 12, 26,
28, 55]. The continuation phase of treatment can be initiated if susceptibility to isoniazid and rifampicin is
confirmed.
It is suggested to treat cases with rifampicin mono-resistance and MDR-TB in centres with experience, to
allow close patient monitoring and adaptation of the treatment regimen on the basis of latest scientific
evidence and forthcoming updated recommendations.
Rifampicin blood levels may be monitored if poor response to treatment due to under-dosing or
malabsorption is suspected [26, 27].
The 2017 WHO TB treatment guidelines advocated the use of adjuvant corticosteroid therapy with
dexamethasone or prednisone during the first 6–8 weeks for TB meningitis [30], in TB pericarditis to
prevent constrictive pericarditis and avoid surgery, in renal TB to prevent ureteric stenosis and in spinal
TB (if evidence of spinal cord compression) [30].
Standard 9 (changed)
A patient-centred approach to treatment, based on the patient’s needs and mutual respect between the
patient and the provider, should be developed for all patients.
Notes
A central element of the patient-centred strategy is the use of measures to assess and promote adherence
to the treatment regimen and to address poor adherence. These measures should be tailored to the
individual patient’s circumstances, based on a detailed clinical and social history, and be mutually
acceptable to the patient and the provider.
Supervision and support should be individualised and should draw on the full range of recommended
interventions and available support services. The aim is to prevent poor adherence before it occurs. Such
measures may include direct observation of medication ingestion (directly observed treatment (DOT) or
video-observed treatment (VOT)) and/or identification and training of a treatment supporter (for
tuberculosis and, if appropriate, for HIV infection) who is acceptable and accountable to the patient and
to the health system. Appropriate incentives and enablers, including financial, social and psycho-social
support, may also serve to enhance treatment adherence [10, 12, 26, 27, 30, 70, 71].
Additional services included in the package of interventions recommended in the 2017 WHO TB
treatment guidelines to support the patient (with drug-susceptible or drug-resistant TB) and promote
adherence [12, 26, 27, 30, 70, 71] are: 1) health education and counselling; 2) tracers or digital medication
monitoring methods; 3) material support to the patients; 4) staff education; and 5) community or
home-based observed treatment.
A decentralised model of service delivery for MDR-TB care is recommended. This approach is more
convenient for patients and might ensure economic savings in some settings.
Standard 10 (changed)
Response to therapy in patients with pulmonary tuberculosis should be monitored by follow-up smear
microscopy and culture, at least, at the time of completion of the initial phase of treatment (two months
for drug-susceptible tuberculosis). If the sputum smear and/or culture are positive at completion of the
initial phase, molecular tests of drug resistance and further DST should be performed promptly. In
patients with extrapulmonary tuberculosis and in children unable to produce sputum, the clinical response
to treatment (weight, inflammatory markers and repeat imaging) is objectively assessed.
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EU specific requirements
Treatment monitoring should be done according to international guidelines [10, 16–18, 23, 25–27]. In the
EU, countries have resources to perform treatment monitoring on a monthly basis. For MDR-TB cases,
this monthly monitoring should be done based on sputum smear and culture [54, 72].
Standard 11 (changed)
An assessment of the likelihood of drug resistance, based on history of prior treatment, exposure to a
possible source case with drug-resistant TB, and the community prevalence of drug resistance, should be
made, especially for patients who are not bacteriologically confirmed or for whom drug susceptibility
testing cannot be performed. Rapid testing (genotypic rifampicin and isoniazid resistance testing and
genotypic/phenotypic second-line drug resistance testing for patients with rifampicin resistance or
MDR-TB) should be performed for all patients as defined in standards 2–4 and 8. Furthermore, patient
counselling and education should begin immediately for all tuberculosis patients, in order to minimise the
potential for transmission. Infection control measures appropriate to the setting should be applied as
recommended in ESTC public health standard 20.
Notes
This standard emphasises the need to use rapid molecular tests to rule-out or confirm presumed MDR-TB
as described in standards 2–4 and 8 [12]. In the near future, other genotypic techniques such as WGS
could be considered.
As expressed in standards 2–4, rapid molecular testing for rifampicin and isoniazid resistance does not yet
rule out the requirement to perform standard DST to confirm results from the molecular test as well as
perform the comprehensive standard DST for other drugs.
Resistance to other second line drugs in Europe is common [73–78].
Phenotypic DST should only be performed and interpreted for drugs with critical concentration and
clinical breakpoints established and fully validated [12, 53].
Genotypic DST should be interpreted based on an agreed list of mutations and interpretations [12, 53]
Standard 12 (changed)
Patients with, or highly likely to have, tuberculosis caused by drug-resistant (especially
rifampicin-resistant/MDR/XDR) organisms should be treated with individualised regimens containing
second-line and add-on anti-tuberculosis drugs. The regimen chosen should be based on confirmed drug
susceptibility patterns. Empirical regimens may cause further resistance and are not recommended, except
for culture-negative tuberculosis.
Depending on the drug susceptibility pattern, treatment with a minimum of five effective anti-TB drugs
should be provided for at least 20 months [12]. If the patient fulfils the eligibility criteria for the standard
shorter MDR-TB regimen (9–11 months) this can be used.
EU-specific requirements
As the treatment of MDR/XDR-TB often represents a last chance to ensure patient cure and survival, a full
range of patient-centred measures, including counselling, observation and support of treatment, as well as
psycho-social support are required to ensure adherence [12, 28–30]. This is particularly important given
that these patients often belong to socially and economically disadvantaged groups.
For the treatment of MDR-TB, no drug should be administered to a patient with documented resistance
(either by molecular or phenotypic DST). Thus, second-line DST should be performed to confirm the
drug resistance pattern as well as to guide the correct choice of treatment.
In the EU/EEA, DST to ethambutol is considered reliable when conducted in quality-assured laboratories
[76]. Pyrazinamide testing could be performed by genotypic (detection of pncA mutations) or phenotypic
test (i.e. growth-based (liquid) automated methods).
The individualised regimen should include at least five effective TB medicines during the intensive phase,
including pyrazinamide and four core second-line TB medicines. Drugs should be chosen as follows: one
chosen from group A, one from group B, and at least two from group C (table 3). If the minimum
number of five effective TB medicines cannot be composed from drugs included in groups A to C, an
agent from group D2 and other agents from group D3 may be added to bring the total to five. If
pyrazinamide cannot be used (e.g. due to resistance or toxicity) an additional agent from group C or D
can be added to strengthen the regimen. Total treatment duration ranges from 20 to 24 months, with the
recommended intensive phase being 8 months [12].
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In patients with rifampicin-resistant TB or MDR-TB, who have not been previously treated with
second-line drugs and in whom resistance to fluoroquinolones and second-line injectable agents has been
excluded or is considered highly unlikely, a shorter MDR-TB regimen of 9–11 months recommended by
WHO may be used instead of the conventional individualised regimen [12, 29, 79].
Treatment with new medicines including bedaquiline and delamanid along with repurposed medicines like
linezolid and clofazamine and second-line medicines to which the M. tuberculosis strain is likely to be
sensitive is required for patients suffering from XDR-TB or those patients suffering from strains resistant
to fluoroquinolones or second-line injectables [77, 80]. For patients with serious adverse events to
fluoroquinolones or second-line injectables new and repurposed medicines can also be considered.
Adverse events following prescription of second-line drugs should be managed according to international
recommendations with the aim of limiting the probability of losing an effective drug due to such adverse
events [10]
Adverse events, as well as the decision to start, modify or interrupt a second-line regimen should be
managed by a team of experts (e.g. “TB Consilium” or similar body,) and not by individual physicians, in
order to minimise mistakes and share responsibilities as well as share experience and expertise [77, 81, 82].
All efforts should be made to avoid development of further drug resistance.
WHO suggested that, in addition to chemotherapy, surgery may be used in selected cases with pulmonary
TB, e.g. those with large cavities confined to one lobe [28]. Further research in this direction is necessary.
Notes
In order to prevent the selection of resistant M. tuberculosis mutants it is essential to never add only one
effective drug to a failing regimen [28].
The “shorter regimen” recommended by WHO is as follows:
4–6 Km-Mfx-Pto-Cfz-Z-H(high−dose)-E/5 Mfx-Cfz-Z-E
Note that in the original Bangladesh study gatifloxacin and not moxifloxacin was used [28].
The WHO criteria preventing the use of the “shorter regimen” include [12, 28, 29, 62, 76, 83–93]:
1) confirmed resistance or presumed ineffectiveness to a medicine in the shorter MDR-TB regimen;
2) exposure to ⩾1 second-line medicines in the shorter MDR-TB regimen for >1 month; 3) intolerance
to ⩾1 medicines in the shorter MDR-TB regimen or risk of toxicity (e.g. drug−drug interactions); 4)
pregnancy; 5) extrapulmonary disease; and 6) at least one medicine in the shorter MDR-TB regimen not
available.
In Europe, the growth-based liquid DST (e.g. the mycobacteria growth indicator tube (MGIT) system) for
ethambutol is considered reliable. Therefore, it might be considered an element of judgement for eligibility
TABLE 3 World Health Organization classification of anti-tuberculosis drugs [28]
Group Drugs Abbreviation
A: Fluoroquinolones Levofloxacin Lfx
Moxifloxacin Mfx
Gatifloxacin Gfx
B: Second-line injectables Amikacin Am
Capreomycin Cm
Kanamycin (streptomycin) Km (S)
C: Other core second-line agents Ethionamide/prothionamide Eto/Pto
Cycloserine/terizidone Cs/Trd
Linezolid Lzd
Clofazimine Cfz
D: Add-on agents (not part of the core MDR-TB
regimen)
D1 Pyrazinamide Z
Ethambutol E
High-dose isoniazid H(high-dose)
D2 Bedaquiline Bdq
Delamamid Dlm
D3 p-aminosalicylic acid PAS
Imipenem-cilastatin Ipm
Meropenem Mpm
Amoxicillin-clavulanate
(thioacetazone)
Amx-Clv (T)
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to the “shorter regimen” [75]. Line probe assays can be used as well, but there are mutations in additional
genes conferring resistance to ethambutol that are not included in these assays. Ethionamide resistance can
be predicted by molecular tests if mutations in inhA or EthA genes are detected by WGS. The association
of inhA mutations with katG mutations makes the strains resistant to any dose of isoniazid [29, 79].
The American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and
Prevention TB treatment guidelines support the use of treatment drug monitoring in different situations,
including difficult-to-treat MDR-TB cases [26, 27].
Given the difficulties in managing patients with rifampicin resistance or MDR-TB, and deciding correctly
on the eligibility to the shorter regimen, referral of these patients to specialised centres is suggested.
Standard 13 (changed)
A written or electronic record of all medications administered, treatment monitoring (including
bacteriologic response), adverse reactions and treatment outcomes, should be maintained for all patients.
EU-specific requirements
At the first contact with each patient, the complete clinical and social history on TB should be collected
and included in the medical records. It should include the available information on previous diagnosis,
treatment (regimen, doses, duration, changes in the regimen, etc.) and adherence, as well as complete
information on bacteriology at diagnosis and during follow-up (sputum smear, culture and species
identification, drug susceptibility testing for first and second-line drugs). This information should be
reported in the documentation released to the patient (discharge letter, transfer-out form or equivalent
document) to facilitate continuum of care if the patient moves/is moved to another health unit [94, 95].
Notes
Reporting forms for the described documentation can be obtained from several sources [23].
WHO has recommended countries to activate aDSM (active tuberculosis drug-safety monitoring and
management) [12, 96, 97].
Depending on resources availability, healthcare providers should consider to follow up MDR-TB cases
after treatment completion to detect early relapse [98].
Standards for addressing HIV infection and comorbidities
Standard 14 (changed)
HIV counselling should be carried out and HIV testing should be recommended to all patients with, or
presumed to have, tuberculosis. Testing is of special importance as part of the routine management of all
patients in areas with a high prevalence of HIV infection in the general population, or if the patient is
from a high-risk population or has symptoms and/or signs of HIV-related conditions. Because of the close
interaction between tuberculosis and HIV infection, integrated approaches to prevention and treatment of
both infections are recommended [99].
Standard 15 (changed)
All patients with tuberculosis and HIV infection should be carefully evaluated: antiretroviral therapy is
recommended in all HIV-positive tuberculosis patients. Tuberculosis treatment should be started
immediately and the antiretroviral treatment prescribed as soon as possible.
Notes
The consideration of treatment with co-trimoxazole was retracted from the ESTC as they refer to HIV
management and prevention of other infections. General prophylactic treatment against other infections is
not relevant in the EU setting. Rather, the risk of HIV-related infections must be considered individually
for each patient based on risk factors and setting, and form the basis for decision to provide prophylactic
treatment against infections other than tuberculosis.
The 2017 WHO treatment guidelines suggest a delay between the initiation of TB therapy and the start of
antiretroviral treatment of at least 14 days to reduce the risk of paradoxical reactions due to immune
reconstitution syndrome [12, 30].
Standard 16 (changed)
Persons with HIV co-infection who, after careful evaluation, have a positive test (TST and/or IGRAs) for
presumed latent infection with M. tuberculosis but do not have active tuberculosis should be offered
preventive treatment.
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EU specific requirements
As HIV co-infection is known to increase the probability of developing active TB disease upon infection,
HIV-seropositive persons who have been in contact with an index case harbouring an MDR-TB strain
should initially undergo an individual risk assessment. Regular clinical monitoring and follow-up should
be provided for those with evidence of latent infection [100].
Preventive treatment should take into account the drug resistance pattern of the source case, the CD4
count and the use of antiretroviral treatment. Preventive treatment should be provided with 6-month
isoniazid, or 9-month isoniazid, or a 3-month regimen of weekly rifapentine plus isoniazid, or 3–4-month
isoniazid plus rifampicin, or 3–4-month rifampicin alone [31, 101]. Rifampicin- and
rifapentine-containing regimens should be prescribed with caution to people living with HIV who are on
antiretroviral treatment due to potential drug-to-drug interactions [31, 32].
Standard 17 (changed)
All providers should conduct a thorough assessment of conditions that could affect tuberculosis treatment
response or outcome. At the time the case management plan is developed, the provider should identify
additional services that would support an optimal outcome for each patient and incorporate these services
into an individualised plan of care. This plan should include assessment of and referrals for treatment for
other illnesses with particular attention to those known to affect treatment outcome, for instance HIV,
diabetes mellitus, drug and alcohol addiction, tobacco smoking, and other psycho-social problems [102].
Services such as antenatal or well-baby care should also be provided when needed.
EU specific requirements
Implementation of the entire package described in the WHO Interim Policy on Collaborative TB/HIV
activities should be performed for all the activities, both those covered here and others included in the
WHO package [99].
Standards for public health and tuberculosis prevention
Standard 18 (changed)
All care providers for patients with tuberculosis should ensure that persons who have been in close contact
with active and infectious TB patients are evaluated and managed in line with international
recommendations. Close contacts include household and family members, and individuals with intensive
or prolonged contact in congregate settings like prisons, homeless or migrant shelters, and indoor spaces
like schools or offices.
The risk of tuberculosis transmission depends on the concentration of the tubercle bacilli in the air, the
airflow, the duration of the contact and the susceptibility of the contact to infection. The determination of
priorities for contact investigation is based on the likelihood that a contact: 1) has undiagnosed and hence
untreated tuberculosis; 2) is at high risk of having been infected by the index case; 3) is at high risk of
developing tuberculosis if infected; and 4) is at risk of having severe tuberculosis if the disease develops.
EU specific requirements
The determinants of TB transmission and susceptibility should be carefully considered when assessing
whether transmission has likely occurred and the need for initiating contact tracing [34].
Close contacts of MDR- and XDR-TB patients should be tested for LTBI and TB according to national
guidelines. Contacts in which TB disease has been excluded and who are diagnosed with LTBI should
undergo an individual risk assessment to determine: 1) the contact’s risk for progression to TB disease;
2) the drug susceptibility pattern of the source case; and 3) the contact’s risk for adverse events if initiating
LTBI treatment [31, 32]. Irrespective of the clinical advice regarding LTBI treatment, these contacts should
be provided with careful clinical observation, information and health education by healthcare workers
experienced in management of LTBI and TB disease [100, 103].
Involvement of local, community-based organisations (including community healthcare workers,
non-clinical professionals and peers), is advisable when conducting contact tracing among vulnerable and
hard-to-reach populations. This approach can contribute to the successful identification of potential
contacts [55, 104].
Clinicians and national programme managers are to interact with the relevant health authorities of host
and/or home countries of TB patients belonging to migrant groups or mobile populations, to ensure
continuum of care and contact investigation as appropriate [105].
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Standard 19 (changed)
Contacts of an infectious tuberculosis patient, persons with HIV-infection, patients initiating anti-tumour
necrosis factor (TNF) treatment, patients receiving dialysis, patients preparing for organ or haematological
transplantation, and patients with silicosis should be tested for latent tuberculosis infection. If latent
tuberculosis infection is identified they should be carefully evaluated for active tuberculosis. When active
tuberculosis is excluded, preventive treatment using a WHO-recommended regimen should be offered.
EU specific requirements
Clinicians should collaborate with public health authorities in implementing adequate contact tracing
procedures, performed according to national and international recommendations on progressive circles,
when an infectious index case is diagnosed and notified [34, 103, 106, 107]. Similarly, both source finding
and contact investigation should be initiated if a child with TB (any site of infection) has been identified
and where no source has been identified [103, 108].
Individuals undergoing treatment with anti-TNF-α should be considered as high-risk contacts. According
to the ESTC number 16, in individuals who are HIV-infected or affected by comorbidities, treatment of
latent infection should be promptly initiated if TB infection is identified by TST and/or IGRAs and active
tuberculosis disease is excluded [31, 32, 34, 63, 109, 110].
Notes
As indicated in ESTC number 18, a comprehensive individual risk assessment and close clinical
monitoring should be provided to close contacts of an MDR-TB or XDR-TB source case irrespective of
the clinical advice regarding LTBI treatment [31, 100].
Treatment for LTBI should be according to national and international recommendations, as outlined in
ESTC number 16 [31, 107]
Standard 20 (changed)
Each healthcare facility caring for patients who have, or are presumed to have infectious tuberculosis,
should develop and implement an appropriate tuberculosis infection control plan.
EU specific requirements
Community-based treatment, supported by infection control measures at home, should be available for
patients preferring to undergo treatment at home [12, 30].
If hospitalisation is required, clinicians should ensure that all newly admitted patients who are
presumed to have infectious TB are subject to respiratory isolation until their diagnosis is confirmed or
excluded [10].
In order to prevent transmission of tubercle bacilli to other patients, staff and/or visitors, smear-positive
TB patients should ideally be isolated in appropriate rooms until they achieve bacteriological conversion
(negative sputum microscopy). Isolation should be in rooms with negative pressure ventilation.
An appropriate infection control plan, managed by a designated person, should include the following four
components; managerial activities; administrative controls; environmental controls; and personal
protection interventions [12, 111]. Adequate administrative measures for tuberculosis infection control
should be in place in all healthcare facilities, as well as adequate respiratory protection measures (including
the use of respirators following respirator fit testing for staff and the use of surgical mask for infectious
patients). Appropriate training on infection control to staff, and standardised health education of patients
on cough etiquette, based on validated tools, should be also included in the infection control plan.
Infection control committees, which cover airborne diseases, and includes infection control experts, should
also be implemented [12, 111–113].
Notes
The implementation of an infection control plan is essential for the treating clinician and health facility as
well as for the overall health system. Clinicians should maintain a dialogue within their health facility,
develop a sound infection control plan, contributing with their technical expertise. The health facility
should engage with all healthcare workers, non-medical staff, patients and visitors and ensure optimal
implementation, practice and monitoring of these infection control measures; all healthcare workers
should be (re)trained in the infection control plan [10, 111, 114–116].
It is important to have a designated infection control focal person with the required authority to ensure
the implementation of the infection control plan.
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With regard to the need of isolating infectious tuberculosis patients, it is important to consider several
options for isolation, and not only that of hospitalisation. For example, a patient with drug-susceptible TB
who can be treated at home (i.e. no need for hospitalisation due to severe health status), does not need to
be hospitalised, as long as appropriate measures for treatment and infection control are ensured at the
residence [111, 117, 118].
Patients with a clinical indication for hospital admission, such as comorbidities, should not be hospitalised
in a general medical ward. Such patients should be placed in rooms that allow appropriate respiratory
isolation.
Standard 21 (unchanged)
All providers must report both new and re-treatment tuberculosis cases and their treatment outcomes to
local public health authorities, in conformance with applicable legal requirements and policies.
EU specific requirements
Clinicians should perform treatment outcome evaluations in their clinical unit at regular time intervals
(e.g. quarterly) [23, 119]. Treatment outcomes should be reported to local public health authorities, in
conformance with applicable requirements and policies and, at the same time, be used as a monitoring
and evaluation tool to improve the quality of patient management. Information on treatment outcome
should also regularly be channelled back from the public health department to the healthcare providers, to
allow a coordinated evaluation of the outcomes. Information on the final outcome of patients should be
available at the clinical unit which initiated treatment, even when the patient is transferred out. Adequate
training must be provided to health staff in charge of reporting treatment outcomes to public health
authorities and performing the quarterly evaluation of the clinic’s own cases. This principle is also
applicable to TB patients moving across EU borders [1, 120–122].
Supporting enablers to the ESTC
In the process of developing the standards and reaching consensus, the panel of experts identified the need
and added-value of identifying and listing “supporting enablers” to the standards. These are a resource for
policymakers, clinicians, public health workers and other stakeholders to identify how best to adopt, adapt,
introduce and implement the ESTCs in their setting with the ultimate goal of securing optimal TB care,
prevention and control
1) Formal adoption of the European Union Standards for Tuberculosis Care, for the care, prevention and
control at national level. This current version of the ESTC is translated into all EU languages, thus
facilitating endorsement by national medical associations and incorporation of the ESTC into training
curricula of health staff [123].
2) Development of consistent tuberculosis control and elimination strategies and policies according to the
principles described in the End TB Strategy [2, 20, 22] and Tuberculosis Action Plan for WHO European
Region 2016–2020 [21], taking into account best practices in and outside Europe [124, 125].
3) Adoption of specific, updated, evidence-based tuberculosis and multidrug-resistant TB guidelines,
together with mechanisms to update them on a regular basis and to monitor their implementation (audit-
and or knowledge, attitudes and practices study (KAP study)-based) [22, 126–128].
4) Planning and organisation of an adequate national laboratory network to ensure that a minimum
sufficient number of mycobacteriology laboratories are in place, allowing implementation of the standards
described in this document (adequate coverage of the country, adequate internal and external quality
assurance procedures in place, sufficient numbers of samples per laboratory to ensure proficiency,
availability of national laboratories with reference functions to support regional and local laboratories, etc.)
[17, 18, 24].
5) Development of policies ensuring the registration and continuous availability of all first- and
second-line TB drugs and add-on agents (e.g. through coordinated procurement with partner countries for
the drugs not registered in the country or which are necessary in small quantities) [22].
6) Securing consistent and adequate funding for TB and MDR/XDR-TB care, prevention and control
that is sufficient to run the activities mentioned in this document. This should include psycho-social
support and coordination of care for all patients, as highlighted in the International Patients’ Charter for
rights to diagnosis and treatment. This applies particularly to patients belonging to vulnerable populations
[22, 69, 129].
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